According to the literature, the APP Ala713Thr mutation is associated with Alzheimer’s disease and cerebral amyloid angiopathy. We describe a case of dementia clinically compatible with frontotemporal dementia in an APP Ala713Thr mutation carrier in which both [18F]Florbetapir PET uptake and Aβ1-42 cerebrospinal fluid levels were normal. Further evidences are required to establish if this association is only incidental.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
StrozykD, BlennowK, WhiteLR, LaunerLJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60, 652–656.
5.
FaganAM, MintunMA, MachRH, LeeSY, DenceCS, ShahAR, LaRossaGN, SpinnerML, KlunkWE, MathisCA, DeKoskyST, MorrisJC, HoltzmanDM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol59, 512–519.
6.
DuboisB, FeldmanHH, JacovaC, StevenT, DeKoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol6, 734–746.
7.
CarterDA, DesmaraisE, BellisM, CampionD, Clerget-DarpouxF, BriceA, AgidY, Jaillard-SerradtA, MalletJ (1992) More missense in amyloid gene. Nat Genet2, 255–256.
8.
RossiG, GiacconeG, MalettaR, MorbinM, CapobiancoR, MangieriM, GiovagnoliAR, BizziA, TomainoC, PerriM, Di NataleM, TagliaviniF, BugianiO, BruniAC (2004) A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology63, 910–912.
9.
ConidiME, BernardiL, PuccioG, SmirneN, MuracaMG, CurcioSA, ColaoR, PiscopoP, GalloM, AnfossiM, FrangipaneF, ClodomiroA, MirabelliM, VassoF, CupidiC, TorchiaG, Di LorenzoR, MandichP, ConfaloniA, MalettaRG, BruniAC (2015) Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. Neurology84, 2266–2273.
10.
MeassoG, CavarzeranF, ZappaláG, LebowitzBD, CrookTH, PirozzoloFJ, AmaducciLA, MassariD, GrigolettoF (1993) The Mini-Mental State Examination: Normative study on an Italian Random Sample. Dev Neuropsychol9, 77–95.
11.
CarlesimoGA, CaltagironeC, GainottiG (1996) The Mental Deterioration Battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol36, 378–384.
MonacoM, CostaA, CaltagironeC, CarlesimoGA (2013) Forward and backward span for verbal and visuo-spatial data: Standardization and normative data from an Italian adult population. Neurol Sci34, 749–754.
14.
NovelliG, PapagnoC, CapitaniE, LaiaconaM, VallarG, CappaSF (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Arch Psicol Neurol Psichiatria4, 477–506.
15.
AppollonioI, LeoneM, IsellaV, PiamartaF, ConsoliT, VillaML, ForapaniE, RussoA, NichelliP (2005) The Frontal Assessment Battery (FAB): Normative values in an Italian population sample. Neurol Sci26, 108–116.
16.
CaffarraP, VezzadiniG, DieciF, ZonatoA, VenneriA (2002) Una versione abbreviata del test di Stroop: Dati normativi nella popolazione italiana. Nuova Riv Neurol12, 111–115.
17.
CaffarraP, VezzadiniG, DieciF, ZonatoF, VenneriA (2002) Rey-Osterrieth complex figure: Normative values in an Italian population sample. Neurol Sci22, 443–447.
18.
KauferDI, CummingsJL, KetchelP, SmithV, MacMillanA, ShelleyT, LopezOL, DeKoskyST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12, 233–239.
19.
KatzS, FordAB, MoskowitzRW, JacksonBA, JaffeMW (1963) Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA185, 914–919.
20.
ScheltensP, BarkhofF, LeysD, PruvoJP, NautaJJ, VermerschP, SteinlingM, ValkJ (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry55, 967–972.
21.
PasquierF, LeysD, WeertsJGE, Mounier-VehierF, BarkhofF, ScheltensP (1996) Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol36, 268–272.
22.
FazekasF, ChawlukJB, AlaviA, HurtungHI, ZimmermanRA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol149, 351–356.
23.
NacmiasB, PiaceriI, BagnoliS, TeddeA, PiacentiniS, SorbiS (2014) Genetics of Alzheimer’s disease and frontotemporal dementia. Curr Mol Med14, 993–1000.
24.
ZhanXH, ZhaGC, JiaoJW, YangLY, ZhanXF, ChenJT, XieDD, EyiUM, MatesaRA, ObonoMM, EhapoCS, WeiEJ, ZhengYZ, YangH, LinM (2015) Rapid identification of apolipoprotein E genotypes by high-resolution melting analysis in Chinese Han and African Fang populations. Exp Ther Med9, 469–475.
25.
DuitsFH, TeunissenCE, BouwmanFH, VisserPJ, MattssonN, ZetterbergH, BlennowK, HanssonO, MinthonL, AndreasenN, MarcussonJ, WallinA, RikkertMO, TsolakiM, ParnettiL, HerukkaSK, HampelH, De LeonMJ, SchröderJ, AarslandD, BlankensteinMA, ScheltensP, van der FlierWM (2014) The cerebrospinal fluid “Alzheimer profile": Easily said, but what does it mean?Alzheimers Dement10, 713–723.
26.
TapiolaT, AlafuzoffI, HerukkaSK, ParkkinenL, HartikainenP, SoininenH, PirttiläT (2009) Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol66, 382–389.
GiacconeG, RossiG, MorbinM, TagliaviniF, BugianiO, BruniA (2002) A713T mutation of APP gene in an Italian family with Alzheimer disease and severe congophilic angiopathy. Neurobiol Aging23(Supp 1), 320.
29.
BernardiL, GeracitanoS, ColaoR, PuccioG, GalloM, AnfossiM, FrangipaneF, CurcioSAM, MirabelliM, TomainoC, VassoF, SmirneN, MalettaR, BruniAC (2009) AβPP A713T mutation in late onset Alzheimer’s disease with cerebrovascular lesions. J Alzheimers Dis17, 383–389.
StensonPD, MortM, BallEV, ShawK, PhillipsA, CooperDN (2014) The Human Gene Mutation Database: Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet133, 1–9.
34.
SchöllM, WallA, ThordardottirS, FerreiraD, BogdanovicN, LångströmB, AlmkvistO, GraffC, NordbergA (2012) Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology79, 229–236.
35.
TomiyamaT, NagataT, ShimadaH, TeraokaR, FukushimaA, KanemitsuH, TakumaH, KuwanoR, ImagawaM, AtakaS, WadaY, YoshiokaE, NishizakiT, WatanabeY, MoriH (2008) A new amyloid variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol63, 377–387.
36.
CairnsNJ, IkonomovicMD, BenzingerT, StorandtM, FaganAM, ShahAR, ReinwaldLT, CarterD, FeltonA, HoltzmanDM, MintunMA, KlunkWE, MorrisJC (2009) Absence of Pittsburgh compound B Detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer’s disease. Arch Neurol66, 1557–1562.
37.
ArmstrongJ, BoadaM, ReyMJ, VidalN, FerrerI (2004) Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett370, 241–243.
38.
CataniaM, Di FedeG, TonoliE, BenussiL, PasqualiC, GiacconeG, MadernaE, GhidoniR, TagliaviniF (2015) Mirror image of the amyloid-β species in cerebrospinal fluid and cerebral amyloid in Alzheimer’s disease. J Alzheimers Dis47, 877–881.
39.
JonesCT, MorrisS, YatesCM, MoffootA, SharpeC, BrockDJH, St. ClairD (1992) Mutation in codon 713 of the beta amyloid precursor protein gene presenting with schizophrenia. Nat Genet1, 306–309.
